WO2021081515A3 - Compositions et procédés pour le traitement du virus de l'immunodéficience humaine - Google Patents

Compositions et procédés pour le traitement du virus de l'immunodéficience humaine Download PDF

Info

Publication number
WO2021081515A3
WO2021081515A3 PCT/US2020/057394 US2020057394W WO2021081515A3 WO 2021081515 A3 WO2021081515 A3 WO 2021081515A3 US 2020057394 W US2020057394 W US 2020057394W WO 2021081515 A3 WO2021081515 A3 WO 2021081515A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
treatment
immunodeficiency virus
human immunodeficiency
Prior art date
Application number
PCT/US2020/057394
Other languages
English (en)
Other versions
WO2021081515A2 (fr
Inventor
Suzanne AKERS-RODRIGUEZ
Leslie W. Tari
Original Assignee
Cidara Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cidara Therapeutics, Inc. filed Critical Cidara Therapeutics, Inc.
Publication of WO2021081515A2 publication Critical patent/WO2021081515A2/fr
Publication of WO2021081515A3 publication Critical patent/WO2021081515A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des protéines de fusion, des conjugués, des compositions, des procédés pour inhiber la croissance virale, et des procédés pour le traitement d'infections virales (par exemple, des infections par le VIH). En particulier, l'invention concerne des protéines de fusion qui comprennent au moins un peptide qui se lie à la glycoprotéine 41 du VIH (gp41) et au moins un monomère du domaine Fc.
PCT/US2020/057394 2019-10-25 2020-10-26 Compositions et procédés pour le traitement du virus de l'immunodéficience humaine WO2021081515A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962973786P 2019-10-25 2019-10-25
US62/973,786 2019-10-25
US202062970495P 2020-02-05 2020-02-05
US62/970,495 2020-02-05
US202062984539P 2020-03-03 2020-03-03
US62/984,539 2020-03-03

Publications (2)

Publication Number Publication Date
WO2021081515A2 WO2021081515A2 (fr) 2021-04-29
WO2021081515A3 true WO2021081515A3 (fr) 2021-06-24

Family

ID=75620890

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/057394 WO2021081515A2 (fr) 2019-10-25 2020-10-26 Compositions et procédés pour le traitement du virus de l'immunodéficience humaine

Country Status (1)

Country Link
WO (1) WO2021081515A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090191221A1 (en) * 2007-12-18 2009-07-30 Shih-Yao Lin Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
WO2016171980A1 (fr) * 2015-04-24 2016-10-27 Bristol-Myers Squibb Company Polypeptides ciblant une fusion du vih
WO2018141089A1 (fr) * 2017-02-04 2018-08-09 中国医学科学院病原生物学研究所 Lipopeptide à large spectre d'inhibition du vih, dérivés de celui-ci, compositions pharmaceutiques et utilisation associées

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090191221A1 (en) * 2007-12-18 2009-07-30 Shih-Yao Lin Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
WO2016171980A1 (fr) * 2015-04-24 2016-10-27 Bristol-Myers Squibb Company Polypeptides ciblant une fusion du vih
WO2018141089A1 (fr) * 2017-02-04 2018-08-09 中国医学科学院病原生物学研究所 Lipopeptide à large spectre d'inhibition du vih, dérivés de celui-ci, compositions pharmaceutiques et utilisation associées

Also Published As

Publication number Publication date
WO2021081515A2 (fr) 2021-04-29

Similar Documents

Publication Publication Date Title
WO2020252393A8 (fr) Compositions et procédés pour le traitement du virus de l'immunodéficience humaine
CR20220552A (es) Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
PH12021550822A1 (en) Compositions and methods for the treatment of viral infections
MX2022015257A (es) Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas.
WO2005111079A3 (fr) Immunogenes de vaccins vih et strategies d'immunisation, destines a eliciter des anticorps anti-hiv-1 a neutralisation large contre le domaine proximal de membrane de vih gp41
WO2021046549A8 (fr) Compositions et procédés pour le traitement d'infections virales
EA201892233A1 (ru) Композиции и способы, связанные с иммуногенами вич-1
WO2006077601A3 (fr) Peptides de fusion vih-1 gp41 pour une immunomodulation
CA3179819A1 (fr) Anticorps anti-glycoproteine spike du sars-cov 2 et leurs fragments de liaison a l'antigene
WO2020106358A8 (fr) Nouveaux anticorps contre le virus zika et utilisations associées
WO2009120339A3 (fr) Vecteurs pour délivrer des agents neutralisant une maladie
CR7806A (es) Inhibidores de la fusion de derivados peptidos de la infeccion vih
MX2018000023A (es) Particulas semejantes a virus recombinantes que utilizan la proteina gag del virus de inmunodeficiencia bovina.
WO2018057967A3 (fr) Constructions ciblant des complexes peptide du vih/cmh et leurs utilisations
WO2021081515A3 (fr) Compositions et procédés pour le traitement du virus de l'immunodéficience humaine
PH12018500468A1 (en) Fusion protein
MX2022002842A (es) Composiciones y metodos para el tratamiento del virus sincitial respiratorio.
MX2022006940A (es) Composiciones farmaceuticas.
MX2021012604A (es) Nuevo inhibidor de mek para el tratamiento de infecciones virales y bacterianas.
WO2003052122A3 (fr) Inhibiteur de gp41
WO2007018550A3 (fr) Compositions et methodes pour detecter une infection par le vih-1/vih-2
WO2021226037A8 (fr) Traitement d'infections virales
MX2019013874A (es) Peptidos y sus usos como agentes antivirales.
BR112022025647A2 (pt) Proteínas quiméricas de rsv e coronavírus, composições imunogênicas e métodos de uso
WO2021021603A3 (fr) Immunogènes e2 de vhc modifiés et compositions de vaccin associées

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20879360

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20879360

Country of ref document: EP

Kind code of ref document: A2